Heparin and cAMP modulators interact during pre-in vitro maturation to affect mouse and human oocyte meiosis and developmental competence by Zeng, H. et al.
 ACCEPTED VERSION 
 
 
Zeng, Haitao; Ren, Zi; Guzman, Luis; Wang, Xiaoqian; McDowall, Melanie Lisa; Ritter, 
Lesley Jane; De Vos, Michel; Smitz, Johan E.; Thompson, Jeremy Gilbert E.; Gilchrist, 
Robert Bruce  
Heparin and cAMP modulators interact during pre-in vitro maturation to affect mouse and 
human oocyte meiosis and developmental competence  
Human Reproduction, 2013; 28(6):1536-1545 
 
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in 
Human Reproduction following peer review. The definitive publisher-authenticated version 
Human Reproduction, 2013; 28(6):1536-1545 is available online at: 
http://humrep.oxfordjournals.org/content/28/6/1536.  
 




















Authors may upload their accepted manuscript PDF ("a post-print*") to institutional 
and/or centrally organized repositories, but must stipulate that public availability be 
delayed until 12 months after first online publication in the journal. Please note that 
a special policy applies for articles published under the Oxford Open initiative - see 
below. 
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in 
[insert journal title] following peer review. The definitive publisher-authenticated version 
[insert complete citation information here] is available online at: xxxxxxx [insert URL 
that the author will receive upon publication here]. 
 
date ‘rights url’ accessed: Friday, 4 April 2014 
1 
 
Heparin and cAMP modulators interact during pre-in vitro maturation to 1 
affect mouse and human oocyte meiosis and developmental competence 2 
  3 
Hai-tao Zeng1,2, Zi Ren1,3, Luis Guzman4,5, Xiaoqian Wang1, Melanie L. Sutton-McDowall1, Lesley J. 4 
Ritter1, Michel De Vos5, Johan Smitz4, Jeremy G. Thompson1 and Robert B. Gilchrist1,*  5 
 6 
1Research Centre for Reproductive Health, Robinson Institute, and Discipline of Obstetrics and 7 
Gynaecology, School of Paediatrics and Reproductive Health, Medical School, University of Adelaide, 8 
Adelaide, Australia  9 
2Department of Obstetrics and Gynaecology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 10 
People's Republic of China 11 
3Center for Reproductive Medicine, General Hospital of Guangdong, Guangzhou, People's Republic of 12 
China 13 
4Laboratory of Follicular Biology, UZ Brussel, Brussels, Belgium 14 
5Center for Reproductive Medicine, UZ Brussel, Brussels, Belgium.  15 
 16 









Study Question: Does heparin ablate the advantageous effects of cAMP modulators during pre-in vitro 24 
maturation (IVM) and have a deleterious effect in standard oocyte IVM? 25 
Summary Answer: Heparin interrupts energy metabolism and meiotic progression and adversely affects 26 
subsequent development of oocytes under conditions of elevated cAMP levels in cumulus-oocyte 27 
complexes (COCs) after pre-IVM treatment with forskolin.  28 
What is Known Already: In animal IVM studies, artificial regulation of meiotic resumption by cAMP 29 
elevating agents improves subsequent oocyte developmental competence. Heparin has no effect on 30 
spontaneous, FSH- or EGF-stimulated meiotic maturation. 31 
Study Design, Size, Duration: An in vitro cross-sectional study was conducted using immature mouse and 32 
human COCs. Depending on individual experimental design, COCs were treated during pre-IVM with or 33 
without heparin, in the presence or absence of forskolin and/or 3-isobutyl-1-methylxanthine (IBMX), and 34 
then COC function was assessed by various means.  35 
Participants/Materials, Settings, Methods: Forty two women with polycystic ovaries or polycystic 36 
ovarian syndrome donated COCs after oocyte retrieval in a non-hCG-triggered IVM cycle. COCs were 37 
collected in pre-IVM treatments and then cultured for 40 hours and meiotic progression was assessed. 38 
COCs from 21-24 day old female CBA F1 mice were collected 46 h after stimulation with equine chorionic 39 
gonadotrophin. Following treatments, COCs were checked for meiotic progression. Effects on mouse 40 
oocyte metabolism were measured by assessing oocyte mitochondrial membrane potential using JC-1 41 
staining and oocyte ATP content. Post-IVM mouse oocyte developmental competence was assessed by in 42 
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vitro fertilization (IVF) and embryo production. Blastocyst quality was evaluated by differential staining of 43 
inner cell mass and trophectoderm layers.  44 
Main Results and the Role of Chance: In the absence of heparin in pre-IVM culture, the addition of cAMP 45 
modulators did not affect human oocyte MII competence after 40 hours. In standard IVM, heparin 46 
supplementation in pre-IVM did not affect MII competence, however when heparin was combined with 47 
cAMP modulators, MII competence was significantly reduced from 65% to 15% (P<0.05). In mouse 48 
experiments, heparin alone in pre-IVM significantly delayed germinal vesicle breakdown (GVBD) so that 49 
fewer GVBDs were observed at 0h and 1h of IVM (P<0.05), but not by 2h or 3h of IVM. Combined 50 
treatment with IBMX and forskolin in the pre-IVM medium produced a large delay in GVBD such that no 51 
COCs exhibited GVBD in the first 1h of IVM, and the addition of heparin in pre-IVM further significantly 52 
delayed the progression of GVBD (P<0.05), in a dose-dependent manner (P<0.01). Combined IBMX and 53 
forskolin treatment of mouse COCs during pre-IVM significantly increased mitochondrial membrane 54 
potential and ATP production in the oocyte at the end of pre-IVM (P<0.05), and significantly improved 55 
fertilization, embryo development and quality (P<0.05). However, heparin abolished the IBMX + 56 
forskolin-stimulated increase in mitochondrial membrane potential and ATP production (P<0.05), and 57 
adversely affected embryonic cleavage, development rates and embryo quality (P<0.05). This latter 58 
adverse combinational effect was negated when mouse COCs were collected in heparin and IBMX for 15 59 
min, washed and then cultured for 45 min in IBMX and forskolin without heparin. 60 
Limitation, Reasons for Caution: Experiments in mice found that heparin ablation of the advantageous 61 
effects of cAMP modulators during pre-IVM was associated with altered oocyte metabolism, but the 62 
mechanism by which heparin affects metabolism remains unclear.  63 
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Wider Implications of the Findings: This study has revealed a novel and unexpected interaction between 64 
heparin and cAMP modulators in pre-IVM in immature mouse and human oocytes, and established a 65 
means to collect oocytes using heparin whilst modulating oocyte cAMP to improve developmental 66 
potential. 67 
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Recovery of immature oocytes followed by in-vitro maturation (IVM) is a potentially useful treatment to 88 
generate mature oocytes for a range of clinical applications including human infertility treatment and 89 
fertility preservation. The major advantages of IVM are avoidance of the risk of ovarian hyperstimulation 90 
syndrome (OHSS), reduced cost, simplified treatment, and reduced anxiety that the short-term and 91 
long-term side effects of repeated ovarian stimulation may have on maternal and fetal health (Chian et 92 
al., 2004). However, in comparison with conventional in vitro fertilization (IVF), in vitro matured oocytes 93 
have been shown to be compromised in embryo quality and developmental potential (Trounson et al., 94 
2001). In general, current approaches to IVM have much lower pregnancy rates than conventional IVF, 95 
with implantation rates rarely exceeding 10 to 15% per embryo transferred and higher early pregnancy 96 
losses (Smitz et al., 2011).  97 
An innovative approach to IVM for application in infertility treatment and fertility preservation is 98 
required to bring this patient-friendly treatment into routine practice. A recent significant clinical 99 
innovation is the approach of vitrifying all embryos in an IVM pick-up cycle, which substantially increases 100 
implantation rates (De Vos et al; 2011, Guzman et al; 2012). In terms of laboratory approaches, solid 101 
gains in the improvement of oocyte competence have been achieved in animal studies by managing 102 
cyclic adenosine mono-phosphate (cAMP) levels during IVM (reviewed; Gilchrist, 2011). Cyclic AMP plays 103 
a critical role in maintaining mammalian oocyte meiotic arrest and inducing maturation in mammalian 104 
oocytes (Conti et al., 2012). Relatively high levels of cAMP within the oocyte are essential to maintain 105 
meiotic arrest, whereas a drop in intra-oocyte concentration of cAMP enables resumption of meiosis and 106 
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maturation (Sela-Abramovich et al., 2006), and this is the mechanism that allows oocytes to 107 
spontaneously mature during IVM. The cornerstone of modern approaches to IVM is to control 108 
cumulus-oocyte complex (COC) cAMP levels to allow synchronization of nuclear and cytoplasmic 109 
maturation processes within the oocyte (Gilchrist, 2011; Smitz et al., 2011). A key outcome of this 110 
approach is the maintenance in vitro of cumulus-oocyte gap junctions, with the objective to prolong the 111 
oocyte maturation period to promote sustained interaction between the immature oocyte with 112 
adequately conditioned cumulus cells (Gilchrist, 2011; Luciano et al., 2011). Maintenance of an 113 
appropriate cAMP concentration seems to be an important requirement to promote chromatin transition 114 
and gradual transcriptional silencing, as part of final oocyte differentiation (Luciano et al., 2011). A large 115 
body of animal and human literature demonstrates that artificial regulation of meiotic resumption by 116 
cAMP elevating agents improves subsequent oocyte developmental competence (Funahashi et al., 1997; 117 
Luciano et al., 1999, 2004; Nogueira et al., 2003a, b, 2006; Thomas et al., 2004; Luciano et al., 2011). Our 118 
previous study found that combined treatment of COCs with the cAMP modulators cilostamide (type 119 
3-specific phosphodiesterase (PDE) inhibitor) and forskolin, positively influenced human oocyte 120 
developmental competence, by exhibiting a synergistic effect on the prevention of loss of gap junctions 121 
and the resumption of meiosis, by increasing COC cAMP levels (Shu et al., 2008). In another approach 122 
termed SPOM (simulated physiological oocyte maturation), we showed using mouse and cow COCs that 123 
the first 1–2 h after oocyte collection is critically important and that treatment with forskolin and 124 
3-isobutyl-1-methylxanthine (IBMX, a non-specific PDE inhibitor) during this period has profound 125 
long-term consequences on oocyte developmental programming (Albuz et al., 2010).  126 
Clinical IVM pick-up aspirates are usually blood laden, which may block the thin IVM aspiration needle, 127 
and typically makes the tightly compacted COCs difficult to identify in the aspirate. Heparin acts as an 128 
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anticoagulant, preventing the formation of clots and extension of existing clots. It is widely used as an 129 
injectable anticoagulant in clinical practice, and can also be used to form an inner anticoagulant surface 130 
on various experimental and medical devices. Therefore, during the clinical practice of IVM and IVF, 131 
follicular fluid is collected in tubes containing saline or PBS containing heparin. Heparin is sometimes 132 
added to collection media in animal IVM research laboratories, although in some species it is often 133 
omitted. When the SPOM approach (Albuz et al., 2010) was applied in a clinical experiment, we noted an 134 
unexpected adverse interaction between heparin and cAMP regulators that prevented human oocyte 135 
maturation. Therefore, in this study we hypothesized that heparin ablates the advantageous effects of 136 
cAMP modulators during pre-IVM, but has no deleterious effects in standard laboratory IVM practice. 137 
Due to the natural shortage of good quality human oocytes for research purposes, the bulk of the 138 
mechanistic investigations of this hypothesis were conducted using the mouse model, where the same 139 
phenomenon was evident. 140 
 141 
 142 
  143 
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MATERIALS AND METHODS 144 
Experimental approvals and reagents 145 
All human oocyte experiments were conducted in Belgium at UZ Brussel, whilst all mouse experiments 146 
were conducted at the University of Adelaide, Australia. Human experiments were approved by the local 147 
ethics committee and each of the oocyte donors gave written informed consent. All mouse experimental 148 
protocols and animal handling procedures were reviewed and approved by the University of Adelaide 149 
Animal Ethics Committee. All of the reagents were purchased from Sigma (St. Louis, MO) unless 150 
otherwise stated. Three kinds of heparin purified from porcine intestinal mucosa were used in this study: 151 
one high molecular weight (17-19 kDa) heparin (Sigma, H3393-1MU) and two low molecular weight (~6 152 
kDa) liquid heparins from DBL (Hospira Australia Pty Ltd, New Zealand) and Leo (LEO Pharma, Belgium). 153 
All mouse experiments were conducted with DBL heparin (DBL) unless otherwise stated.   154 
 155 
Clinical and laboratory aspects of human IVM 156 
Forty two consecutive patients and healthy oocyte donors with ultrasound-only polycystic ovaries (PCO) 157 
or polycystic ovarian syndrome (PCOS) consented to donate oocytes for IVM research at UZ Brussel. 158 
Briefly, all women received 150 IU/day highly purified human menopausal gonadotrophin (Menopur; 159 
Ferring Pharmaceuticals) for three days, starting on day three after spontaneous menstruation or 160 
withdrawal bleeding. An ovarian ultrasound scan was performed on day six to rule out the emergence of 161 
a dominant follicle. All patients underwent transvaginal ovarian puncture for immature oocyte retrieval 162 
on cycle day seven. No hCG trigger was administered. COCs were retrieved with a 17-gauge single-lumen 163 
needle (K-OPS-1230-VUB; Cook Medical, Brisbane, Australia), with an aspiration pressure of 70 mm Hg 164 
and collected into pre-IVM media from Cook Medical; either version 1 (without cAMP-modulators) or 165 
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version 2 (with forskolin and IBMX), with or without heparin at 10 IU/mL (Heparin Leo®, Leo Pharma, 166 
Belgium). Follicular aspirates were filtered (Falcon 1060; 70 mm mesh size) and COCs were collected from 167 
the culture dish and incubated in pre-IVM media with treatments for 1 hour. Collected COCs were then 168 
washed and cultured individually in 96-well dishes (Costar 3696; Corning. New York, USA), each well 169 
containing 75 µL of IVM culture media (version 1; Cook Medical) that had been pre-equilibrated at 37°C 170 
and 6% CO2 and supplemented with 100 mIU/mL FSH and 0.25 µM cilostamide. After 40 hours of IVM 171 
culture, COCs were mechanical dissociated using hyaluronidase (Cook Medical) under a stereomicroscope 172 
and maturation was assessed under an inverted microscope. These pre-IVM and IVM treatments were 173 
designed to test the efficacy of the SPOM IVM approach in humans under clinical conditions (Albuz et al., 174 
2010). 175 
 176 
Mouse COC collection and pre-IVM treatments 177 
Immature female CBA F1 mice that were 21-24 days of age were housed in a temperature-controlled and 178 
light-controlled room. Immature COCs were collected 46 h after administration of 5 IU of equine 179 
chorionic gonadotrophin (eCG; Folligon, Intervet, The Netherlands). Puncture of mouse ovaries and 180 
collection of COCs from large antral follicles was performed in HEPES-buffered alpha minimal essential 181 
medium (MEM; Invitrogen, Carlsbad, USA) supplemented with 3 mg/ml bovine serum albumin (BSA) 182 
(ICP BiologicalTM, New Zealand) and 1 mg/ml fetuin. All experimental interventions in this study were 183 
during the 1 hour pre-IVM phase and hence were conducted in collection medium in HEPES-aMEM 184 
medium. Depending on individual experimental design, COCs were exposed during pre-IVM to the 185 
adenylate cyclase activator, forskolin (50 µM), with or without the PDE inhibitor IBMX (50 µM) and 186 
heparin (50 IU/ml). Millimolar stock concentrations of the forskolin and IBMX were stored at -20°C 187 
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dissolved in anhydrous dimethylsulphoxide and were diluted fresh for each experiment. COCs were 188 
maintained in pre-IVM treatments under atmospheric conditions at 37°C for 1 h. At the end of the 189 
pre-IVM phase, COCs were washed twice in their respective IVM treatments, before transfer to IVM 190 
drops.  191 
 192 
Mouse IVM 193 
Mouse COCs were matured in bicarbonate-buffered MEM medium supplemented with 3 mg/ml BSA. 194 
For experiments measuring germinal vesicle breakdown (GVBD) as the primary outcome (figure 2A and 195 
figure 3), COCs were cultured in HEPES-buffered MEM medium supplemented with BSA without FSH for 196 
1 h at 37°C under atmospheric conditions, or for 3 h (figure 2B) at 37°C in pre-equilibrated 197 
bicarbonate-buffered MEM medium (with BSA, without FSH) in 6% CO2 in humidified air. In the 198 
experiments where meiosis was assessed (figures 2, 3 and 5), COCs were denuded of cumulus cells at the 199 
designated time points and checked for meiotic progression by light microscopy. Where IVM preceded 200 
IVF (figure 5), groups of 30-40 COCs were matured in 500 µl drops of pre-equilibrated 201 
bicarbonate-buffered MEM medium supplemented with 50 mIU/ml recombinant human FSH (Puregon, 202 
Organon), BSA and 1 mg/ml fetuin, overlaid with mineral oil and incubated at 37°C with 5% CO2 in 203 
humidified air for 18 h prior to IVF. 204 
 205 
Mouse IVF and embryo culture  206 
The effect of treatments on oocyte developmental competence was assessed by examining the capacity 207 
of the oocyte post-IVM to support pre-implantation embryo development. Mouse IVF and embryo 208 
culture were performed as previously described (Albuz et al., 2010). All media used were the Vitro 209 
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Research Media series generously donated by Cook Medical (Brisbane, Australia). Mouse IVM/embryo 210 
experiments were replicated 4 times.  211 
 212 
Differential staining of mouse blastocysts 213 
On Day 5 of embryo culture, blastocysts and hatching blastocysts were subjected to a differential staining 214 
protocol for identification of cells within the inner cell mass (ICM) and trophectoderm (TE) layers 215 
(Dunning et al., 2010). The zona was dissolved by incubation in 0.5% pronase at 37°C. Blastocysts were 216 
then transferred to 10 mM tri-nitrobenzenesulfonic acid for 10 min at 4°C, followed by incubation in 0.1 217 
mg/ml of anti-dinitrophenyl-BSA for 10 min at 37°C, then 5 min at 37°C in guinea pig serum containing 10 218 
μg/ml of propidium iodide. Blastocysts were then stained overnight in 6 μg/ml of bisbenzimide in ethanol 219 
at 4°C. The following day, blastocysts were washed in 100% ethanol and mounted on a siliconized slide in 220 
a glycerol drop. The number of pink (TE) and blue (ICM) fluorescent cells was assessed, blinded to 221 
treatment group, using a fluorescent microscope and Hg lamp, with an ultraviolet excitation wavelength 222 
dichroic mirror at 400× magnification. 223 
 224 
Assessment of mouse oocyte metabolism after pre-IVM culture 225 
To determine ATP levels within oocytes, COCs were cultured in their respective pre-IVM treatments for 1 226 
hour and then denuded of cumulus cells.  For each sample preparation, 10 oocytes from each treatment 227 
were collected in 10 μl of ice cold distilled water and snap-frozen and stored at −80°C for later analysis. 228 
The measurement of ATP content in oocytes was performed with an ApoSENSORTM ATP Assay Kit 229 
(BioVision, CA, USA) according to the manufacturer’s instructions. The assay utilizes the enzyme 230 
luciferase to catalyze the formation of light from ATP and luciferin, and light was measured by using a 231 
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TRIADTM Series Verification Plate (DYNEX, VA, USA). A duplicated 5-point standard curve (0, 0.5, 1, 2 and 3 232 
µM of ATP) was included in the assay. Oocyte ATP content was calculated using the formula derived from 233 
the linear regression of the standard curve. Five replicate experiments were conducted using 80-120 234 
oocytes/treatment/replicate.  235 
 236 
The mitochondrial membrane potential sensitive fluorescence dye, JC-1 (Molecular Probes, Eugene, OR), 237 
was used to measure the activity of oocyte mitochondria. Low-polarized mitochondria (δΨm ≤ –100 mV) 238 
fluoresce green and high-polarized mitochondria (δΨm ≥ –140 mV) fluoresce yellow-red, reflecting the 239 
formation of JC-1 multimers or J-aggregates (Reers et al., 1995). The stock concentration of the dye was 1 240 
mM in dimethyl sulfoxide. The dye was diluted in culture medium before use. COCs were cultured in their 241 
respective pre-IVM treatments for 1 hour, then denuded of cumulus cells and oocytes were cultured for 242 
15 minutes in their respective treatments with 2 µM JC-1. Oocyte fluorescence was observed using a 243 
narrow green filter (490-540 nm) and a narrow red filter (570-620nm), using a FluoView FV10i Confocal 244 
Microscope (Olympus, Japan). The laser-power and photomultiplier settings were kept constant for all 245 
experiments. A single optical scan through the center of the oocyte was used for the analysis. The images 246 
were processed and red and green fluorescence intensities of JC-1 in oocytes was measured and analysed 247 
using the inbuilt software of the FluoView FV10i Confocal Microscope. Three replicate experiments were 248 
conducted using 10-20 oocytes/treatment/replicate. 249 
 250 
Statistical analysis 251 
Statistical analyses were conducted using the Statistical Package for Social Sciences 18.0 (SPSS, Chicago, 252 
IL). Treatment effects were assessed by Chi-square test (human COC experiment) or one-way analysis of 253 
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variance followed by either Dunnett’s or Bonferroni’s multiple-comparison post-hoc tests to identify 254 
individual differences between means. All values are presented as means with their corresponding SEM. 255 
Statistical significance was set at P<0.05. 256 
 257 
Results 258 
Effect of heparin on meiotic maturation of human COCs treated with/without cAMP modulators 259 
In the absence of heparin in pre-IVM, the addition of cAMP modulators (pre-IVM, forskolin + IBMX; IVM, 260 
cilostamide) did not affect human oocyte MII competence after 40 hours (Fig 1A). Heparin alone in 261 
pre-IVM did not appreciably affect MII competence, however when combined with cAMP modulators, MII 262 
competence was significantly (P<0.05) reduced from 65% to 15% (Fig 1B), suggesting an adverse 263 
interaction between pre-IVM heparin and the pre-IVM cAMP modulators forskolin and IBMX, on human 264 
oocyte maturation.  Hence, subsequent experiments were conducted using the mouse experimental 265 
model to investigate in further detail the nature of such an interaction.  266 
 267 
Effect of heparin with/without IBMX and forskolin in pre-IVM on subsequent GVBD of mouse COCs 268 
As expected, treatment with IBMX and/or forskolin during pre-IVM significantly lowered the rates of 269 
GVBD at designated time points in IVM, when compared with controls (p<0.05). As shown in Fig. 2A and 270 
2B, heparin alone in pre-IVM also significantly (p<0.05) decreased GVBD at 0h and 1h of IVM, but not by 271 
2h or 3h of IVM. Furthermore, an additive effect of heparin and IBMX and/or forskolin in pre-IVM was 272 
observed, whereby heparin further inhibited GVBD in each IBMX/forskolin treatment combination 273 
(p<0.05). In the combined treatment of IBMX and forskolin in pre-IVM, oocytes commenced GVBD after 2 274 
h of IVM, however the addition of heparin in pre-IVM further significantly decreased GVBD rates for the 275 
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first 3h of the IVM phase (p<0.05) (Fig. 2B). 276 
 277 
As there are many different heparin variants, each with different vehicles and preservatives, we 278 
examined the capacity of different types of heparin to interact with cAMP modulators in pre-IVM, on 279 
subsequent meiotic resumption in IVM. When used together with IBMX and forskolin in pre-IVM, both 280 
low molecular weight liquid injectable heparin variants containing preservatives (~6kDa; Leo and DBL), 281 
and a high molecular weight, ostensibly preservative-free, powdered heparin (17 – 19 kDa; Sigma), 282 
inhibited GVBD to comparable extents after 2 hour of IVM (P<0.05, Fig. 3A). In the presence of IBMX and 283 
forskolin in pre-IVM, there was a significant dose-dependent inhibition of oocyte GVBD during the IVM 284 
phase (P<0.01, Fig. 3B). This experiment yielded higher GVBD rates than those in Fig 2, which we 285 
attribute to a different operator using subtly different denuding techniques and efficiency of assessment 286 
which, in the absence of a PDE inhibitor in IVM, have large affects on GVBD rates in mouse oocytes. All 287 
other mouse experiments in this study used DBL heparin at 50 IU/ml. 288 
 289 
Effect of IBMX, forskolin and heparin on energy metabolism in mouse oocytes  290 
Cyclic AMP is generated from ATP and hence treatment during pre-IVM with IBMX and/or forskolin is 291 
likely to impact on COC metabolism. Relative to levels at collection from the follicle, intra-oocyte ATP 292 
levels did not change after 1 h of pre-IVM treated with 50 µM IBMX or 50 µM forskolin (Fig. 4A). However, 293 
combined IBMX and forskolin treatment of COCs during pre-IVM significantly increased ATP 294 
concentration in the oocyte after 1 h (p<0.05). Heparin had no affect on oocyte ATP levels in the 295 
presence of IBMX, tended to decrease levels in the presence of forskolin (p=0.102), and abolished the 296 
increase in ATP concentration in the presence of IBMX and forskolin (p<0.05), generating less than half 297 
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the ATP content (Fig. 4A). This latter adverse combinational effect was negated when COCs were 298 
collected in heparin and IBMX for 15 mins, washed and then cultured for 45 mins in IBMX and forskolin 299 
without heparin, to the extent that ATP levels were restored to levels comparable to IBMX + forskolin 300 
(p>0.05; Fig 4A). 301 
 302 
We also examined oocyte mitochondrial activity after pre-IVM treatments using the mitochondrial 303 
membrane stain JC-1. As shown in figs. 4B and 4C, in the control group of COCs undergoing GVBD, the 304 
ratio of red/green fluorescence intensity was more than doubled (p<0.05) from 0 h to 1 h of pre-IVM 305 
culture. Although the ratio was also significantly increased from collection to 1 h when treating with 306 
heparin (p<0.01), it was nonetheless lower than the 1 h control (p<0.01). With any combination of IBMX 307 
+/- forskolin +/- heparin, the majority of oocytes were still at the GV stage after 1 h of pre-IVM (Figs 2, 308 
4C), when JC-1 staining was performed. When treated with IBMX, regardless of the presence of heparin, 309 
oocyte mitochondrial membrane hyper-polarisation levels were significantly (p<0.05) lower than in 310 
control oocytes (1 h). In the absence of heparin, when compared with IBMX, forskolin seemed more 311 
effective at increasing the ratio of red/green fluorescence intensity in oocytes (p<0.01). IBMX notably 312 
amplified this stimulating effect of forskolin (Figs 4B, 4C; p<0.05), supporting the observed elevated ATP 313 
levels in this treatment group (Fig 4A). However, heparin abolished the stimulation of mitochondrial 314 
function by forskolin (p<0.01), and it was more apparent in treatment with IBMX and forskolin, with less 315 
than half the ratio of red/green fluorescence intensity in these oocytes (p<0.01). 316 
 317 
Effect of heparin with/without IBMX and forskolin in pre-IVM on subsequent maturation and 318 
developmental competence of mouse oocytes  319 
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To determine the developmental consequences of pre-IVM treatment with heparin with/without IBMX 320 
and forskolin, following pre-IVM, COCs were subjected to standard IVM (with FSH), IVF and embryo 321 
culture to day 5 (Fig. 5). Whilst IBMX and forskolin initially delayed meiotic resumption (Fig. 2), these 322 
oocytes were not delayed in reaching MII, but rather the treatment promoted increased maturation of 323 
oocytes to the polar body stage compared to the control (Fig. 5A, 87.3%, P<0.05). In the absence of IBMX 324 
+ forskolin, heparin had no effect on the maturation rate when compared to control (P>0.05), but 325 
significantly (p<0.05) reduced maturation in the presence of IBMX + forskolin. Compared with the control, 326 
pre-IVM with IBMX and forskolin significantly increased cleavage, blastocyst and hatched blastocyst rates 327 
(Fig. 5B-D, P<0.05). IBMX and forskolin also improved embryo quality, reflected in an increased ICM cell 328 
number and a higher ratio of ICM/total cells compared with the control (Fig. 5E, 5F, P<0.05). Heparin 329 
alone had no adverse effect on cleavage or embryo development rates or on embryo quality compared 330 
to the control (P<0.05).  However, when combined with IBMX and forskolin, heparin significantly 331 
decreased the cleavage rate (Fig 5B; P<0.05) compared to the control group, and notably antagonized the 332 
beneficial effects of forskolin and IBMX, in terms of cleavage and hatched blastocyst rates, ICM cell 333 
numbers and ICM/total cell numbers (Fig 5; P<0.05). 334 
 335 
As heparin + IBMX + forskolin combined in pre-IVM adversely affected the majority of parameters of COC 336 
function assessed in this study, but the combination of heparin + IBMX only weakly inhibited GVBD of 337 
oocytes and had no harm on mitochondrial activity (Fig. 1 and 3), the effect of this treatment on oocyte 338 
maturation and subsequent developmental competence was assessed. Compared to the control, 339 
treatment during pre-IVM with heparin and IBMX for 1 hour had no effect on oocyte maturation, 340 
cleavage, blastocyst or hatched blastocyst rates, or on subsequent blastocyst cell numbers (Fig. 5). When 341 
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COCs were collected in medium with IBMX and heparin for 15 mins, and then washed and transferred to 342 
medium with IBMX and forskolin without heparin for 45 mins (IH-IF; Fig 5), oocyte maturation, cleavage 343 
and hatched blastocyst rates were all significantly (p<0.05) higher than when COCs underwent pre-IVM 344 




Mammalian oocyte maturation in vitro and subsequent developmental competence is influenced to a 349 
great extent by the culture media and culture conditions employed, including the addition of hormones, 350 
growth factors and other specific signal transduction regulators (Gilchrist, 2011). There is now a large 351 
body of evidence that management of oocyte and cumulus cell cAMP during IVM is desirable and is an 352 
effective means to enhance oocyte developmental competence (Smitz et al., 2011). Consistent with 353 
previous studies using a cAMP-mediated biphasic-IVM approach (Funahashi et al., 1997; Nogueira et al., 354 
2003a; Nogueira et al., 2003b; Shu et al., 2008; Vanhoutte et al., 2009) and with simulated physiological 355 
oocyte maturation (Albuz et al., 2010), compared to standard IVM, elevating COC cAMP in this study 356 
generated higher rates of mouse oocyte maturation and embryo development and improved embryo 357 
quality, as reflected in an increased hatched blastocyst rate and ICM size. This was achieved by rapidly 358 
increasing cAMP levels in COCs with forskolin and IBMX for just the one hour pre-IVM phase. However, 359 
under such elevated cAMP conditions, the inclusion of heparin in pre-IVM media affected human and 360 
mouse oocyte maturation, and had a notable detrimental interaction with forskolin on mouse oocyte 361 
metabolism and subsequent developmental potential. By contrast, collection medium with IBMX and 362 
heparin caused a transient arrest in oocyte meiotic resumption, without compromising subsequent 363 
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maturation and fertilization, suggesting that this may be a good clinical option for oocyte collection when 364 
using cAMP modulators. 365 
In our study, in the absence of cAMP modulators, heparin had no affect on the capacity of human or 366 
mouse oocytes to complete meiosis, but delayed mouse oocyte meiotic resumption. Heparin did not 367 
completely prevent GVBD during spontaneous maturation, but delayed it so that after 2 hours oocytes 368 
exhibited similar GVBD rates to spontaneously maturating oocytes in heparin-free culture. These results 369 
are consistent with previous studies showing generally a benign effect of heparin on standard oocyte 370 
meiotic maturation. Heparin has no effect on spontaneous, FSH- or EGF-stimulated murine meiotic 371 
maturation (Eppig, 1981; Downs, 1989). In bovine COCs, the addition of heparin under standard IVM 372 
conditions may affect the kinetics of GVBD and possibly MII, without notably affecting COC cAMP levels 373 
(Fenton et al., 1993; Flores-Alonso et al., 2008). These minor affects of heparin in standard IVM are 374 
consistent with the almost universal use of heparin as an additive to clinical IVM collection media (human 375 
and veterinary). 376 
It has however been known for decades that heparin and other glycosaminoglycans affect matrix 377 
formation and cumulus expansion of in vitro maturing COCs, albeit in a highly species-specific manner. In 378 
mice, heparin blocks hyaluronic acid synthesis and cumulus expansion of COCs stimulated by FSH, 379 
epidermal growth factor (EGF), prostaglandin E (PGE) or dbcAMP (Eppig, 1981), whereas heparin 380 
stimulates cumulus expansion in bovine COCs independent of FSH or cAMP (Fenton et al., 1993). Watson 381 
et al. (2012) recently found that heparin is likely to prevent mouse cumulus expansion by binding to 382 
endogenous GDF9 and disrupting its interaction with heparan sulphate proteoglycan coreceptor(s) on 383 
cumulus cells, important for GDF9 signaling and cumulus cell function in the periovulatory follicle. Hence, 384 
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the addition of heparin to IVM COCs is likely to have significant effects on oocyte-secreted GDF9 385 
signalling to cumulus cells and thereby on cumulus cell differentiation and function, although this may 386 
not account for the more acute temporal effects of heparin observed in this study on oocyte meiotic 387 
resumption and maturation. 388 
In general, in the current study, there was a notable adverse interaction between heparin and the 389 
combined cAMP modulators on most aspects of human and mouse oocyte function assessed.  Heparin 390 
further inhibited GVBD in mouse oocytes incubated with either IBMX or forskolin, and this was 391 
exacerbated when IBMX and forskolin were combined in pre-IVM. Under these pre-IVM conditions, 392 
heparin dose-dependently inhibited mouse oocyte GVBD during the IVM phase. In addition, human 393 
oocyte maturation was all but prevented when COCs were collected in heparin together with forskolin 394 
and IBMX. The mechanism by which heparin additively inhibits GVBD of GV-stage oocytes in the presence 395 
of IBMX and forskolin in pre-IVM is currently unclear.  396 
 397 
There is no clear evidence to our knowledge that heparin affects COC cAMP levels, but heparin interrupts 398 
the actions of Ca2+ in COCs. In the majority of fully grown, immature mouse oocytes, repetitive transient 399 
Ca2+ oscillations occur every 2–3 minutes and last for 2–4 hours soon after release from the antral follicles 400 
(Carroll et al., 1994). Ca2+ influx occurs in oocytes, mostly via L-type Ca2+ channels and gap junctions 401 
(Eppig and Downs, 1984), and Ca2+ influx decreases as maturation progresses (Tosti et al., 2000). The 402 
acquisition of meiotic competence is related to the functionality of the IP3 pathway and, correspondingly, 403 
to the oocyte's ability to generate spontaneous cytoplasmic IP3-dependent calcium oscillations (Lefèvre et 404 
al., 1997). Heparin is a well known inositol 1,4,5-trisphosphate (IP3) receptor antagonist and 405 
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microinjection of heparin into bovine oocytes suppresses spontaneous Ca2+ oscillations and inhibits GVBD 406 
(Homa, 1991).  407 
 408 
In the current study, it was evident that when mouse COCs were stimulated with forskolin, heparin 409 
interrupted the metabolism of the oocyte with decreased mitochondrial activity and ATP production. This 410 
may be as a result of interrupting the actions of high cAMP in regulating Ca2+ transport processes from 411 
endoplasmic reticulum (ER) to mitochondria. Increased cAMP can induce Ca2+ rises and the accumulation 412 
of Ca2+ (Dolphin, 1999), which can affect communication between the endoplasmic reticulum (ER) and 413 
mitochondria (Vandecasteele et al., 2001; Mendes et al., 2005; Szabadkai and Duchen, 2008). The ER and 414 
mitochondria are closed endomembrane networks which control different aspects of cellular metabolism. 415 
Close apposition of IP3-gated channels (IP3 receptors) to the mitochondrial surface enables the uptake of 416 
Ca2+ by mitochondria during cell stimulation (Vandecasteele et al., 2001; Mendes et al., 2005). Heparin 417 
prevents IP3 interacting with its receptor, and thus inhibits the Ca
2+ release from internal stores and 418 
induces a Ca2+ drop. Thus, we suggest that the notably decreased oocyte metabolism may be caused by 419 
heparin-mediated interruption of cAMP/calcium intra-cellular signaling and that this in turn adversely 420 
affected oocyte meiotic and developmental competence.   421 
In this study, treatment of mouse COCs during pre-IVM with IBMX and forskolin had notable positive 422 
effects on oocyte meiotic maturation, embryo cleavage and blastocyst rates and embryo quality, as well 423 
as impacting COC metabolism, particularly mitochondrial activity and ATP availability.  This is generally 424 
consistent with our previous mouse and bovine study (Albuz et al., 2010) which showed that oocyte 425 
developmental competence is improved by treating COCs at collection with either forskolin or IBMX to 426 
prevent loss of COC cAMP and to substantially increase COC cAMP levels, as occurs during in vivo oocyte 427 
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maturation (Schultz et al., 1983). Perhaps surprisingly, combined IBMX and forskolin treatment of mouse 428 
COCs during pre-IVM did not deplete the oocyte of ATP but rather significantly increased ATP production 429 
in the oocyte after 1 hour. In such an in vitro scenario, when COCs are treated with forskolin, cAMP is 430 
principally generated by cumulus cells from cumulus cell ATP and is then transported to the oocyte via 431 
gap junctions (Thomas et al., 2002). The increased oocyte ATP levels after forskolin and IBMX treatment 432 
correlated to increased oocyte mitochondrial activity. Cyclic AMP can diffuse in the cell where it can set 433 
up localized gradients in subcellular structures (Zaccolo et al., 2002), and it can also be produced directly 434 
in the mitochondrial matrix by the soluble adenylyl-cyclase localized in this compartment (Zippin et al., 435 
2003). Cyclic nucleotide (cAMP and cGMP) phosphodiesterases have been found in the inner and outer 436 
mitochondrial membranes (Cercek and Houslay, 1982). These adenylyl-cyclases and phosphodiesterases 437 
can modulate the mitochondrial level of cAMP (Baillie et al., 2005). In humans (Papa et al., 2001) and 438 
other mammals (Technikova-Dobrova et al., 2001), cAMP-dependent phosphorylation of complex I 439 
subunits is associated with stimulation of the NADH-ubiquinone oxidoreductase activity of the complex, 440 
resulting in enhancement of overall cellular respiration (Papa, 2006). This may be a means by which 441 
forskolin and IBMX could stimulate mitochondrial membrane potential and thereby ATP production by 442 
the oocyte, to generate high oocyte maturation and blastocyst rates and improved embryo quality.  443 
Heparin is a necessary reagent used in clinical IVM aspirations as it prevents blood clotting and greatly 444 
assists COC collection. By contrast, research IVM laboratories using oocytes from animals post-mortem, 445 
typically use no heparin (mouse) or low/no heparin (domestic species) during the oocyte collection phase. 446 
As the use of heparin with forskolin was harmful to oocyte maturation and subsequent competence 447 
(current study), we sought to explore this interaction further in order to find an optimal medium 448 
combination for clinical COC aspiration and collection, which enhances embryo yield from IVM oocytes. 449 
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When mouse COCs were collected with heparin and IBMX, but without forskolin, no adverse effect of 450 
heparin on mitochondrial membrane polarity or ATP synthesis was detected, and similar oocyte 451 
maturation and developmental competence rates were achieved, compared to the control with heparin. 452 
Moreover, a feasible option to achieve high blastocyst formation rates, was to collect COCs in medium 453 
with IBMX and heparin, then transfer to pre-IVM medium with forskolin and IBMX (IH-15min + IF-45min; 454 
Figure 5).  455 
This study has confirmed that, under standard pre-IVM and IVM conditions, heparin exposure during 456 
pre-IVM has benign effects on oocyte maturation and developmental potential, but that under elevated 457 
cAMP conditions during pre-IVM, heparin adversely affects oocyte energy metabolism, oocyte meiotic 458 
maturation and subsequent embryo development. Collecting oocytes with IBMX and heparin may be a 459 
good option for pre-IVM where forskolin is used in clinical applications.  460 
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Figure Legends 1 
Figure 1. Interaction of heparin with cAMP modulators (forskolin and 3-isobutyl-1-methylxanthine [IBMX]) 2 
on human oocyte meiotic maturation. Immature human cumulus-oocyte complexes (COCs) were 3 
aspirated from antral follicles and held in pre-in vitro maturation (IVM) treatment medium for 1 h, either 4 
A) without heparin or B) with heparin with or without forskolin and IBMX, and then cultured in IVM 5 
medium for 40 h. Columns represent the maturation rate after IVM culture. Columns from left to right 6 
represent the following number of COCs (A, 71 and 102; B 34 and 240). *Significantly different (P<0.05) 7 
to –cAMP modulator. 8 
 9 
Figure 2. Effect of heparin with and without 3-isobutyl-1-methylxanthine (IBMX) and forskolin during pre- 10 
in vitro maturation (IVM), on germinal vesicle breakdown (GVBD) rates of mouse oocytes after 1 hour of 11 
IVM (A), and on the kinetics of GVBD during pre-IVM and IVM (B). Mouse cumulus-oocyte complexes 12 
(COCs) were collected and held in each treatment medium for 1 h (pre-IVM), then washed, cultured in 13 
treatment-free IVM medium for 1 h (A) or for defined periods up to 3h (B), then denuded and assessed 14 
for GVBD. Columns of (A) from left to right represent the following number of mouse COCs (294, 359, 137, 15 
205, 159, 268, 232 and 226). Lines of (B) from left to right (0h, 1h, 2h, 3h) represent the following number 16 
of mouse COCs (control: 131, 119, 137, 148; heparin: 127, 152, 136, 159; IBMX + forskolin: 135, 128, 149, 17 
162; IBMX + forskolin + heparin: 143, 133, 157, 140).  Data points represent mean + SEM of three to 18 
eight replicates. *Significantly different (P<0.05) to –heparin condition (A) and control group (B); 19 
#significantly different (P<0.05) to IBMX + forskolin group (B). 20 
 21 
Figure 3. (A) Effect of heparin type in pre-in vitro maturation (IVM) with and without 22 
31 
 
3-isobutyl-1-methylxanthine (IBMX) and forskolin on germinal vesicle breakdown (GVBD). (B) Effect of 23 
heparin dose in pre-IVM medium containing IBMX and forskolin on subsequent mouse oocyte GVBD.  24 
Mouse cumulus-oocyte-complexes (COCs) were collected and held in each treatment medium for 1 h 25 
(pre-IVM), then washed, cultured in treatment-free IVM medium for 1 h, then denuded and assessed for 26 
GVBD. Data points represent mean + SEM of four (A) and three (B) replicates. Columns from left to right 27 
represent the following number of COCs (A: 102, 111, 93, 125, 82 and 104; B: 119, 62, 101 and 77).  28 
*Significantly different (P<0.05) to –heparin condition (A), and means within a graph with different letters 29 
are significantly different (P<0.05) (B). 30 
 31 
Figure 4. Effect of heparin in pre-in vitro maturation (IVM) with and without 3-isobutyl-1-methylxanthine 32 
(IBMX) and forskolin on mouse oocyte ATP content (A) and mitochondrial activity (B, C) at the end of 33 
pre-IVM. Mouse cumulus-oocyte-complexes (COCs) were collected; without culture (0 h control), or COCs 34 
were held in each treatment medium for 1 h (pre-IVM), including in one treatment where COCs were 35 
exposed to IBMX + heparin for 15 mins (IH – 15 min) followed by IBMX + forskolin without heparin for 45 36 
mins (IF – 45 mins). Thereafter COCs were denuded, washed, and either immediately snap frozen for ATP 37 
measurement (A), or cultured for a further 15 mins with JC-1 before assessment of mitochondrial 38 
function (B, C). In (A) a total of 600 oocytes in each treatment were assay in 50 oocytes/test tube.  (B) 39 
Columns from left to right represent the following number of oocytes (41, 25, 46, 28, 66, 44, 39, 60 and 40 
55).  Data points represent mean +SEM of five (A) and three (B) replicate experiments. Means with no 41 
common superscripts are significantly different (P<0.05).  42 
 43 
Figure 5. Effect of heparin in pre-in vitro maturation (IVM) with and without 3-isobutyl-1-methylxanthine 44 
32 
 
(IBMX) and forskolin on the subsequent meiotic and developmental competence of mouse oocytes. 45 
Mouse cumulus-oocyte-complexes (COCs) were collected and held in each treatment medium for 1 h 46 
(pre-IVM), including in one treatment where COCs were exposed to IBMX + heparin for 15 min (IH – 15 47 
min) followed by IBMX + forskolin without heparin for 45 min (IF – 45 min). After pre-IVM COCs were 48 
washed, cultured in treatment-free IVM medium for 18 h, and then either; denuded and assessed for 49 
meiotic maturation (A), or COCs were fertilized in vitro and cultured for 5 days (B-D). Blastocyst quality 50 
was assessed with differential staining by cell number of ICM (E) and ratio of ICM/total blastocyst cell 51 
number (F). Columns of (A - D) from left to right represent the following number of oocytes (109, 127, 52 
130, 137, 119 and 134), and columns of (E) and (F) from left to right represent the following number of 53 
analyzed blastocysts (23, 19, 29, 19 ,22 and 23). Data points represent mean +SEM of four replicates. 54 
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